Improving Biomarker Driven Precision Therapy in NSCLC ~ 9/29/21 *CNEs offered*




Biomarker based testing and a precision medicine based approach has become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and is crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients but the discovery of novel molecular targets and subsequent development of a targeted therapy, make it critical to find ways to overcome these barriers. In time as treatment progresses, resistance mechanisms to commonly used targeted therapies are found by the integration of precision medicine. One specific target is the ALK-rearrangements which has become the second most common mutation [with available treatment approved] for metastatic NSCLC.


It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand new data and complexity to tailor treatment selection using a precision medicine based approach in both first line and subsequent line therapies


Learn clinical pearls needed to attain best outcomes for your patients with ALK-mutated NSCLC from expert faculty utilizing case studies and interactive knowledge polls.


This program is supported by an educational grant from Pfizer.


More detailed information including continuing education credit information can be found at: https://www.bucme.org/live/12889


Click to REGISTER



28 views0 comments